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Abstract: The design of early-phase studies of putative screening markers in clinical populations is discussed. Biological, 
epidemiological, statistical and computational issues all affect the design of early-phase studies of these markers, but there 
are frequently little or no data in hand to facilitate the design. Early-phase studies must be designed as part of a development 
program, considering the ﬁ  nal use of the marker, directly informing the decision to made at the study’s conclusion. There-
fore, they should test for sensitivity and speciﬁ  city that would be minimally acceptable to proceed to the next stage of 
development. Designing such trials requires explicit assumptions about prevalence and false positive and negative costs in 
the ultimate target population. Early discussion of these issues strengthens the development process, since enthusiasm for 
developing technologies is balanced by realism about the requirements of a valid population screen. Receiver operating 
characteristic (ROC) curves, which are useful descriptive tools, may be misleading when evaluating tests in low-prevalence 
populations, because they emphasize the relationship between speciﬁ  city and sensitivity in the range of speciﬁ  city likely to 
be too low to be useful in mass screening applications. 
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Introduction
Prototypical research programs for early detection markers, using technologies such as SELDI, have 
been presented by Pepe (Pepe 2001). This ﬁ  ve-phase concept leaves many degrees of freedom for the 
design of studies within the phases. As investigators in an Early Detection Research Network Clinical 
and Epidemiological Center (EDRN-CEC), we are interested in the design of trials which ﬁ  t into the 
early part of Pepe’s Phase II, which could be called early validation or pre-validation studies. These 
would typically be the ﬁ  rst studies conducted in association with investigators independent of the 
laboratory that developed the assay. They may be on archived samples, or samples that are collected 
prospectively. Since both biological samples that are prospectively obtained and archived samples that 
have been drawn from clinical protocols are expensive to harvest, document and maintain, pre-validation 
tests of assays must be carefully designed for the samples’ efﬁ  cient use.
The context of this discussion may be made more concrete by consideration of a simple example. Sup-
pose a developmental laboratory has assayed twenty serum samples that have been collected over time from 
colon cancer patients, and twenty serum samples from patients who had colonoscopies, but did not have 
cancer. The assay produces a single numerical value, and the laboratory reports a two-standard deviation 
difference between the cases and the controls, generating signiﬁ  cant interest. What is the next step?
In this paper, we discuss criteria for design of these trials, and contend that, rather than consider the 
trial as a standalone event, it must be designed in the context of the research program, considering the 
ultimate application of the marker. Critical elements are the minimum criteria for acceptable sensitivity 
and speciﬁ  city, the method of the estimation of the endpoints, and the nature of the cases and controls 
to be tested. We will demonstrate these issues primarily by means of small Monte Carlo simulation 
experiments that are representative of those used to justify clinical trial designs.
General design criteria
The key features of early validation trials are that they are part of a development program and they are 
expensive. The implication of the ﬁ  rst feature is that the least expensive internally valid trial may not 
be the best trial to conduct, since it may not contribute to the developmental decisions that must be made. 26
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The second feature is generally realized as a severe 
constraint on the number of samples available.
The intended application of the marker deter-
mines the structure of the developmental program, 
but a major goal of the research program is to deﬁ  ne 
the application. The research program therefore 
has a number of sequential, conditional decisions. 
Trials should produce sufﬁ  cient information so that 
these decisions, which may include termination of 
the development program, can be made with con-
ﬁ  dence. This implies that trials should be ade-
quately powered to test hypotheses. The following 
questions, each of which could be reformulated as 
a testable hypothesis, are commonly unanswered 
in the early phase of a developmental program 
and would be good candidates for goals of early 
validation trials:
Clinical vs. population screen: Will the marker 
be used as a screen of a large, untested population, 
where prevalence is likely to be low, or in a clinical 
setting, where the prevalence is likely to be orders 
of magnitude higher, but patients are likely to have 
other disease?
Standalone vs. panel: Is the marker to be used in 
isolation, or in combination with existing markers, 
or markers yet to be tested? Will it be used in com-
bination with demographic and risk information?
Asymptomatic vs symptomatic normals: Will it 
be used to distinguish patients with cancer from 
other patients, or patients with pre-cancerous con-
ditions, or subjects with biological risk factors for 
cancer, from healthy people?
In the colon cancer example, the next develop-
mental step may be to assess the adequacy of the 
sensitivity and speciﬁ  city of the marker in patients 
with adenomas or cancers versus healthy volun-
teers who are veriﬁ  ed cancer-free. A design that 
simply estimates the sensitivity and speciﬁ  city may 
not be sufﬁ  cient, since it may present a result that 
is scientiﬁ  cally valid, but insufﬁ  ciently conclusive 
to determine the course of the research program. 
For instance, consider a trial that recruits twenty 
cases and twenty controls (based on 80% power 
for a two-sample t-test on a continuous marker 
having a two-standard-deviation effect size) and 
has the result in Table 1.
The numbers in parentheses are the 95% 
likelihood ratio conﬁ  dence intervals (Collett 1991) 
for the speciﬁ  city (assessed in the controls) and the 
sensitivity (assessed in the cases). The intervals 
cover too large a range to determine if the marker 
is adequate, and the study will have to be repeated 
with a larger sample size. This could have been 
avoided by considering the minimal criteria for 
developing the marker as a population screen at 
the design phase of the study.
Example of a design for a pivotal trial
The answer to the ﬁ  rst question in Section 2 hinges 
upon the sensitivity and speciﬁ  city of the test. 
Constrained by a limited number of samples, it is 
tempting to design an early validation trial by ask-
ing the question, “How sensitive and speciﬁ  c is the 
marker?” This leads to a trial with an arbitrary 
sample size and an equivocal result, since it will 
be driven by the width of the estimated conﬁ  dence 
intervals, or, more likely, the width of the estimated 
conﬁ  dence intervals will be determined by an the 
size of an easily obtained sample. A better question 
is, “Are the sensitivity and speciﬁ  city big enough 
to develop this test as a population screen?”
The big-enough criterion is deﬁ  ned by decision 
theory. Consider the risk-minimizing decision rule 
in Equation 1 (for a derivation, see Hand 1981).
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This decision rule applies to all statistical clas-
siﬁ  ers, including Fisher’s linear (or quadratic) 
discriminant analysis, nearest-neighbor classiﬁ  ca-
tion, logistic regression, recursive partitioning 
trees (also known as CART), neural networks and 
Table 1: Results of a test that classiﬁ  es cases versus controls. The 
numbers in parentheses are 95% likelihood ratio conﬁ  dence intervals 
for proportions.
  To Control To Case
From Control 19/20
(0.75,0.99)
1/20
From Case 5/20 15/20
(0.51,0.91)27
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vector support machines. Different classiﬁ  ers are 
simply different estimators for the ratio of class-
conditional probability density functions on the 
left-hand side of the decision rule. The right-hand 
side of the decision rule represents the level of 
evidence required to classify a patient represented 
by a vector of variables, x, as a case. The value π 
is the prevalence of cases in the target population, 
which cannot in general be estimated from a case-
control study. C-/C+ is the estimated ratio of the 
cost of a false negative to a false positive error. 
The prevalence and cost ratios are inherent in any 
statistical classiﬁ  cation problem; if they are not 
considered, statistical packages set the right-hand 
side of Equation 1 equal to 1, which may not be a 
sensible value. The risk-minimizing decision rule 
is directly related to the Receiver Operating Char-
acteristic (ROC, Swets, et al. 2000) curve by 
Equation 2:
  ROC
(1
′ =⋅
+
−
−π
π
) C
C
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That is, given an ROC curve, the optimal com-
bination of sensitivity and speciﬁ  city are deter-
mined by the point on the curve with the slope as 
described in Equation 2. The application of the 
optimal rule to the preliminary data generated by 
the colon-cancer screening example, assuming a 
prevalence of 300/100,000 and a C- / C+ ratio of 
100, is demonstrated in Figure 1.
This suggests a trial design algorithm for the 
question “Are the sensitivity and speciﬁ  city of the 
marker large enough to warrant its use as a popu-
lation screen?”
1. Determine a consensus on: the prevalence in 
the screening population, π; the cost ratio, C- / C+; 
the sensitivity, γ1, required for the marker as a 
population screen.
2. Plug these assumptions into Equation 1 to 
determine the required speciﬁ  city, δ1.
3. Select the signiﬁ  cance level, α, and power, 
1-β. The signiﬁ  cance level could be adjusted to 
maintain the experiment-wise Type I error. Since 
this is an early-phase test, α can be set relatively 
high (say, 0.1).
4. Deﬁ  ne the null hypotheses γ  γ0  γ1 and 
δ  δ0  δ1, that the sensitivity and speciﬁ  city are 
not large enough, on the cases and controls, respec-
tively.
5. Determine the number of cases and controls 
to achieve the stated power for one-sided exact 
binomial tests and the stated signiﬁ  cance levels if 
γ = γ1 and δ = δ1. It is likely that the number of 
controls will be larger than the number of cases 
because the required speciﬁ  city is likely to be 
higher than the required sensitivity.
Estimation of sensitivity and 
speciﬁ  city
In the previous section, we discussed the criteria 
for the null hypothesis of a clinical trial to estimate 
sensitivity and speciﬁ  city. In a randomized trial to 
test the difference between the means of two 
populations, the criteria described, along with a 
signiﬁ  cance level (α) and power (1-β) are sufﬁ  -
cient to determine the sample size. But the exper-
imental situation in a trial of a prospective marker 
is usually more complicated, because part of the 
study is the construction of a statistical classiﬁ  cation 
model, comprising both the selection of prediction 
Figure 1: ROC curve fora normally-distributed univariate random 
vari  able. The sensitivity and speciﬁ  city values that minimize the 
expected classiﬁ  cation cost for the given prevalence and C-/C+ 
values is displayed.
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π=300/100,000variables from a set of candidate markers (which, 
for example, in a SELDI model, may be the set of 
all identiﬁ  ed peaks in the spectrum, or even all the 
M/Z values in the spectrum, and hence very large 
in number) and the construction of the classiﬁ  ca-
tion function. The selection of variables and con-
struction of the classiﬁ  er is generally referred to 
as training, and the estimation of sensitivity and 
speciﬁ  city is termed testing. Some authors (e.g., 
Burke4), further distinguish between a testing set 
and a validation set.
The sensitivity, speciﬁ  city and other measures 
of the quality of a statistical classiﬁ  er are character-
ized by using the classiﬁ  er to evaluate samples of 
known class membership (case or control) and 
determine the proportions of cases and controls 
correctly classiﬁ  ed. Using all of the available cases 
and controls to train the classiﬁ  er, and then submit-
ting all of those cases to the classiﬁ  er, called re-
substitution, tends to produce a phenomenon 
known as over-ﬁ  tting, which causes the estimates 
of sensitivity and speciﬁ  city to be optimistically 
biased. Alternatives to re-substitution are the use 
of an independent test set, which is not used to train 
the classiﬁ  er function, and cross-validation. In 
cross-validation, observations are held out one at 
a time, and the classiﬁ  er is trained without consid-
ering the withheld observation. Then, the withheld 
observation is classiﬁ  ed, thereby achieving inde-
pendence of training and testing at the cost of a 
small reduction in the efﬁ  ciency of the training. 
Cross-validation is easy and inexpensive when 
used with discriminant analysis, logistic regression 
or nearest-neighbor classiﬁ  cation, but is more dif-
ﬁ  cult or, at least, computationally expensive, with 
other classiﬁ  cation methods.
The effect of re-substitution is demonstrated by 
the display of the Monte Carlo experiment in 
Figure 2. In this experiment, the number of training 
observations for Fisher’s linear discriminant func-
tion (LDF) was held constant at 30, half cases and 
half controls. The number of variables used to dis-
criminate between the two classes, graphed on the 
horizontal axis, was varied from 1 to 10, but the 
total separation between the classes was held con-
stant; the experiment was replicated a total of 10,000 
times. The proﬁ  les display the mean, over 1,000 
replications, of the accuracy, equal to the fraction 
of all observations (cases and controls) correctly 
classiﬁ  ed, using the three estimation methods. The 
horizontal line shows the accuracy possible if the 
class-conditional probability distribution functions, 
and hence the coefﬁ  cients of the LDF, were known 
rather than estimated from the training sample. It is 
seen that, as the number of variables used to classify 
the observations is increased, the positive bias of 
the re-substitution estimate of the accuracy signiﬁ  -
cantly increases. Also, the cross-validation estima-
tor of accuracy is close to, but slightly less than, the 
independent test set estimator. The accuracy of the 
latter two estimators declines as the number of 
variables increases because the number of coefﬁ  -
cients that must be estimated (in the LDF, 
2p +p(p+1)/2) is increasing. The independent test 
set estimator appears to be slightly more accurate 
than cross-validation estimator because one more 
training observation is available for coefﬁ  cient 
estimation, but this slight increase in accuracy is 
purchased at the cost of the test set.
Figure 2: Monte Carlo simulation (10,000 replications) demonstrating 
predictive accuracy of a statistical classiﬁ  er based on 15 training 
cases and 15 training controls. Re-substitution estimates accuracy 
by reclassifying the training observations using classifying 
function, cross-validation recalculates the classiﬁ  er by leaving the 
training observation to be classiﬁ  ed out of the parameter estima-
tion, and an independent test set is used for the third estimator. 
The horizontal line indicates the optimal accuracy that can be 
achieved if the within-class distributional parameters are known 
rather than estimated from the training set.
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From the experiment described in Figure 2, we 
observe that, even when the variables to be used in 
the classiﬁ  er are ﬁ  xed in advance, the re-substitution 
estimator signiﬁ  cantly over-estimates the accuracy, 
the over-estimation increases as the number of 
parameters estimated, relative to the number of 
training samples, increases, and the cross-validation 
estimator achieves nearly the same accuracy as the 
independent test set estimator. Given a fixed 
number of cases and controls, should an indepen-
dent test set be held out, or should the classiﬁ  er be 
cross-validated? Figure 3 demonstrates an answer 
to the question when the classiﬁ  er is based on a 
linear function of the data (e.g. LDF or logistic 
regression) and the variables to be used in classi-
ﬁ  cation are known in advance. Here, sixty observa-
tions are classiﬁ  ed two ways, by dividing them into 
equal-sized training and testing sets, and by using 
all sixty observations in a cross-validated classi-
ﬁ  er. It is seen that, since there are almost twice 
as many training observations available to the 
cross-validated classiﬁ  er than the independent test 
set classiﬁ  er, it is more accurate, and displays less 
variation in accuracy. This example demonstrates 
that, if the variables used for prediction are known, 
cross-validation, if possible (given the method of 
classification), uses the observations more 
efﬁ  ciently than holding some aside from coefﬁ  cient 
estimation as a test set.
The situation is complicated when the selection 
of variables is part of the training. As is pointed 
out elsewhere in this volume (Burke 2004), 
estimates of sensitivity, speciﬁ  city and accuracy 
based on an independent test set are no longer 
unbiased when the test set has been used repeatedly 
as part of an iterative variable selection process. 
In this case, the testing set rather than the training 
set will be over-ﬁ  t, and sensitivity, speciﬁ  city and 
accuracy will still be over-optimistically estimated. 
As we have seen, where computationally feasible, 
the cross-validation estimator makes more efﬁ  cient 
use of the data than a separate testing sample. 
Hence, at the variable-selection stage, there is no 
justiﬁ  cation for using a holdout sample if cross-
validation is possible, but the ﬁ  nal estimates of 
sensitivity, speciﬁ  city and accuracy thereby derived 
are not of the same quality as in the case where the 
variable set is ﬁ  xed, and a separate validation set 
must be used after the variable selection process 
to ensure unbiased estimates of sensitivity and 
speciﬁ  city.
Size of the training set
In Section 3, we proposed a design to test a 
hypothesis set appropriate for a pre-validation 
trial. The sample sizes derived there apply to the 
test or validation set, given that the variables have 
been selected and the classiﬁ  er has been trained. 
How large should the training set be? There is no 
answer to this question general enough to apply 
to all statistical classiﬁ  ers, and designers of trials 
frequently resort to heuristics, such as ‘10 obser-
vations per variable.’ In order to give some struc-
ture to the problem, we propose three sets of 
experimental situations: the variables have been 
selected and only parameter estimation is 
necess  ary; variables must be selected among 
thousands of candidates, as in SELDI or mi-croarray 
analysis; variables must be selected from a limited 
number.
Figure 3: Monte Carlo simulation (10,000 replications) demonstrating 
predictive accuracy of a statistical classiﬁ  er based on 30 cases 
and 30 controls. Cross-validation estimator pools all 60 cases and 
recalculates the classiﬁ  er by leaving out the training observation to 
be classiﬁ  ed. The independent test set classiﬁ  er splits the cases 
and controls in half and uses the ﬁ  rst half for training and the 
second half for testing. The vertical bars connect the ﬁ  rst and third 
quartiles of the observed accuracies, while the proﬁ  les connect the 
medians. The horizontal line is deﬁ  ned as in Figure 2.
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Parameter estimation only: when the variables 
have been selected, then unbiased estimates of 
sensitivity and speciﬁ  city are available through 
cross-validation, so that the testing set is the train-
ing set, and arguments like those in Section 3 may 
suggest an appropriate sample size. If estimates of 
within-class distributions of the markers are avail-
able, Monte Carlo simulations can be used to test 
if a given increase in the sample size would sig-
niﬁ  cantly increase the precision of the parameter 
estimates and thereby increase the quality of the 
estimates of sensitivity and speciﬁ  city.
Variables must be selected among thousands of 
candidates: the phenomenon of the inﬂ  ation of 
the Type I error rate when performing many uni-
variate hypothesis tests has been well-known at least 
since Fisher’s work (Fisher 1935) in the 1930’s. In 
this case, p-values corresponding to univariate 
hypothesis tests may be useful to order the possible 
indicators with respect to further interest, but they 
are not directly interpretable without some further 
adjustment by, for instance, inﬂ  ating the estimate 
of standard errors in the denominators of t-tests 
(Dutoit 2002), using permutation tests to adjust 
p-values (Efron, et al. 2001), or a minimum absolute 
effect size criterion to t-statistics. This makes it 
difﬁ  cult, if not impossible, to apply the usual power 
calculations, or even to effectively simulate the 
process. It is also more likely that a nonlinear clas-
siﬁ  cation techniques will be more appropriate for 
this application. Possibly the only design criteria 
that can be applied are ‘10 observations per variable’ 
or, simply ‘as many as possible.’
Variables must be selected from a limited 
number: this represents a situation somewhere 
between the ﬁ  rst case, where simple simulations 
and, possibly, analytic criteria, can determine a 
useful sample size, and the second, where even 
simulated solutions are intractable. Because 
variable selection methods are sequential, analytic 
derivations of Type I error rates and power are 
difﬁ  cult if not impossible, but the variable selection 
process can be simulated. A typical situation is:
  1.      There are a ﬁ  xed number of samples, say 
50 cases and 50 controls.
2.     Variable selection will be performed on 
the training set, and hence,
3.     A holdout (validation) sample will be 
reserved for unbiased estimates of sensi-
tivity, speciﬁ  city and accuracy.
How should the samples be allocated between 
the training and validation sets? Consider the 
experiment depicted in Figure 4. In this Monte 
Carlo experiment, replicated 14,000 times, either 
2 or 10 discriminator variables were generated 
from a multi-variate normal distribution with a 
randomly generated correlation structure and vari-
ance adjusted so that the Mahalanobis distance 
between the two populations was constant across 
the simulations. Stepwise linear discrminant 
analysis was used to select variables based on a 
training set of n observations, and then the ﬁ  nal 
discriminator was validated on the remaining 100-n 
cases and controls. The distribution of the achieved 
accuracy as the training sample size (n) was 
increased from 20 to 80 (and the validation sample 
size was decreased from 80 to 20) is graphed. If 
the population parameters were known, predictive 
accuracy of about 0.68 is possible. In the top frame, 
when p=2, the predictive accuracy increases from 
0.61 to 0.66. But, when p=10, a more realistic 
Figure 4: Monte Carlo simulation of 14,000 trials of 100 cases and 
controls divided into a training set and a validation set. Variables 
are selected using stepwise linear discrimination, and then used to 
classify the observations in the validation set. The top panel shows 
the median predictive accuracy, where the vertical bars indicate 
the 9
th and 95
th percentiles. The bottom bars show the median, 5
th 
percentile and 95
th percentile of the width of the 95 percent 
likelihood ratio conﬁ  dence interval of the predictive accuracy.
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situation, increasing the training sample from 20 
to 80 has almost no effect; the sample size is inad-
equate in any case. The bottom frame shows the 
width of the likelihood ratio conﬁ  dence interval 
around the accuracy, which is a function of the 
validation sample size. It is seen that, when the 
number of variables is small, over-allocation of 
observations to the training set, thereby reducing 
the size of the test set, produces unnecessarily large 
conﬁ  dence intervals. When the number of variables 
is large, in effect, the training sample is too small 
in all cases, so that allocation of cases to the train-
ing sample only increases the width of the ﬁ  nal 
conﬁ  dence interval, without any signiﬁ  cant gain 
in accuracy.
Discussion
At the early validation stage of the research 
program, there are a number of possible objectives 
to a trial. Some non-pivotal goals might be to 
technically develop (tweak) an assay on a broader, 
more representative or better-described sample, or 
characterize sources of variation in an assay, such 
as sample collection, shipping or processing pro-
cedures, genetic factors or dietary factors. Threats 
to assay validity or patient acquisition strategies 
might be evaluated. Because the number of samples 
is limited, it is tempting to describe pre-validation 
studies as feasibility or pilot studies to achieve one 
or more of these non-pivotal objectives, but this 
strategy increases the total number of samples used 
before critical decisions can be made.
Pivotal goals in early validation trials include: 
establish the feasibility of the use of a marker as a 
classiﬁ  er (question: can a useful classiﬁ  er be con-
structed, which may not be obvious with a high-
dimensional marker such as SELDI); assess the 
adequacy of sensitivity and speciﬁ  city in patients 
(question: are the sensitivity and speciﬁ  city good 
enough for development as a population screening 
tool); assess the adequacy of sensitivity and speciﬁ  c-
ity in tissue (question: does the marker in the sampled 
medium represent the marker in pre-cancerous or 
cancerous tissue). All of these pivotal goals suggest 
either choices about how the marker will be used or 
if it warrants further development. Non-pivotal goals 
can be included as secondary objectives.
Some trial designers contend that all objectives 
of a trial requiring the assessment of sensitivity 
and speciﬁ  city can be accomplished by construct-
ing the ROC curve, and that the area under the 
ROC curve (AUC), or a portion of it, constitutes 
an appropriate univariate outcome against which 
a trial may be powered. While the ROC curve is a 
useful tool for describing the attributes of some 
classiﬁ  ers (those that are measured on a continuous 
scale), it is not particularly useful in population 
screening bio-marker validation trial design, 
because: the ROC curve does not naturally conform 
to the decision-making context of the biomarker 
development program; there is no standard for how 
big an AUC, or how big a change in the AUC, is 
scientiﬁ  cally signiﬁ  cant; most of the ROC curve 
is irrelevant to a population screening marker.
To demonstrate this last point, consider the ROC 
curve presented in Figure 1, which corresponds to 
the serum biomarker example. Based on an initial, 
statistically signiﬁ  cant t-test, this marker would 
generate sufﬁ  cient scientiﬁ  c interest to move to an 
early validation study. The risk-minimizing deci-
sion rule is related to the ROC curve by Equation 2, 
demonstrating that, for a discriminator with this 
degree of separation, and under the specified 
prevalence estimates and cost assumptions, the 
sensitivity would have to be driven down to 0.75 
before the speciﬁ  city would be high enough to 
prevent an excess of false positive cases in a 
screening application. For most population screen-
ing applications, the speciﬁ  city must be in excess 
of 0.95 to avoid a large number of false positives. 
Therefore, 19/20 of the ROC curve is not relevant 
to the decision.
There are several criticisms to the use of cost 
and prevalence data in the design of early valida-
tion trials:
It is too early to consider these factors. If 
prevalence and cost are not considered, the deci-
sion to develop the marker as a population screen, 
clinical marker or panel component is simply 
delayed, and a trial designed to identify modest 
discrimination will have to be repeated with a 
larger sample size.
There will never be a consensus on the estimate 
of C-/ C+. It is not necessary that a particular value 31
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be chosen in advance and treated as inviolate. It is 
useful, however, to check if, given the prevalence 
estimate (about which there should be agreement), 
the proposed sensitivity and speciﬁ  city criteria 
imply an assumption about the C- / C+ ratio that is 
patently absurd. It should be stressed that these 
costs are always inherent in statistical classiﬁ  ca-
tion, so even if they are not explicitly considered, 
they are implicitly present, interacting with the 
ratio (1 – π) / π in Equation 1. Given that human 
beings are not very good at mentally manipulating 
ratios involving very small or very large numbers, 
it is prudent to perform a reality check.
It is only necessary to do better than an existing 
marker. Since many markers used in clinical appli-
cations have truly dismal characteristics, the utility 
of using scarce resources to replace a mediocre 
marker with a somewhat better but still mediocre 
marker is questionable. Realistic decisions 
are made on the basis of analyses of absolute ben-
eﬁ  ts to clinical or epidemiological applications, 
independent of the scientiﬁ  c interest in the biology 
of the marker.
All the information can be derived from the ROC 
curves. If a marker is inherently continuous, the 
ROC curve does provide a useful tool for investi-
gating some its features. But, the visual qualities 
of the ROC curve tend to overemphasize the impor-
tance of the sensitivity in the region of lower 
speciﬁ  city, where a practical marker is unlikely to 
lie. Hypothesis tests based on the area under the 
ROC curve have the same problem; the AUC is 
dominated by the the region of the ROC far to the 
right of a useful clinical or population screen. 
Hypothesis tests based on partial areas require a 
decision about which portion of the ROC curve is 
relevant, returning us to the original problem of 
asserting the most important value of speciﬁ  city, 
which is systematically done by calculating the 
optimal value of ROC′ using cost and prevalence 
assumptions.
The cost criteria will tend to set the bar too high. 
One of the early decision points of a marker is 
population screen versus clinical tool versus panel 
component. The bar must be set high to use a 
marker as a population screen, because this is the 
most rigorous application. Many clinicians would 
argue, for instance, that the prostate specific 
antigen, which currently represents the gold stan-
dard for prostate cancer screening, is insufﬁ  ciently 
speciﬁ  c for that application. Deciding a marker is 
not useful as a standalone population screen does 
not mean it should not be developed. But, the 
research programs for population screens, clinical 
tools and panel components are quite different, and 
the decision about which course should be followed 
should be made as soon as possible in the develop-
ment program.
In this paper, we have asserted that, given the 
developmental context and high cost of samples, 
even early validation trials on markers should be 
designed to satisfy decision-theoretic criteria. 
While some reliance on heuristics is probably 
unavoidable, we have also suggested that, while 
many of the issues in trial design are resistant to 
analytic solutions, relatively simple Monte Carlo 
simulations can be be used to estimate the operat-
ing characteristics of trials, even those where some 
model-building is inherent. We believe that, if early 
trials are considered as part of a development pro-
cess and are more rigorously designed using the 
tools we have presented, that the ultimate cost of 
design programs can be reduced, bringing poten-
tially valuable markers to the clinic and the general 
community sooner.
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